Kymera Therapeutics Ownership | Who Owns Kymera Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Kymera Therapeutics Ownership Summary


Kymera Therapeutics is owned by 93.47% institutional investors, 1.31% insiders, and 5.22% retail investors. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 9.03% of KYMR shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.78% of its assets in Kymera Therapeutics shares.

KYMR Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockKymera Therapeutics93.47%1.31%5.22%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Price t rowe associates inc /md/6.87M9.03%$276.39M
Baker bros. advisors lp6.00M7.88%$241.22M
Wellington management group llp5.31M6.97%$213.51M
Bvf inc/il5.16M6.78%$207.66M
Avoro capital advisors5.15M6.77%$207.18M
Atlas venture life science advisors4.90M6.43%$196.98M
Vanguard group4.89M6.42%$196.62M
Fmr4.83M6.35%$194.33M
Blackrock4.16M5.87%$124.04M
Blackrock funding, inc. /de4.36M5.72%$175.25M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Atlas venture life science advisors4.90M24.03%$196.98M
Merck772.16K12.04%$31.06M
Aquilo capital management183.52K11.13%$7.38M
Bvf inc/il5.16M7.04%$207.66M
Siren2.97M5.28%$119.47M
Redmile group1.10M3.09%$44.27M
Avoro capital advisors5.15M2.93%$207.18M
Foresite capital management vi146.33K2.62%$5.89M
Baker bros. advisors lp6.00M2.58%$241.22M
Artal group3.01M2.29%$89.72M

Top Buyers

HolderShares% AssetsChange
Merck772.16K12.04%772.16K
Wellington management group llp5.31M0.04%688.97K
Avoro capital advisors5.15M2.93%650.00K
Deerfield management company, l.p. (series c)593.00K0.45%593.00K
Blackrock4.16M0.00%499.77K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---600.33K
Redmile group1.10M3.09%-292.82K
Fmr4.83M0.01%-278.72K
Frontier capital management150.17K0.06%-242.09K
Great lakes advisors---156.38K

New Positions

HolderShares% AssetsChangeValue
Merck772.16K12.04%772.16K$31.06M
Deerfield management company, l.p. (series c)593.00K0.45%593.00K$23.86M
Ecor1 capital350.00K0.53%350.00K$14.08M
Foresite capital management vi146.33K2.62%146.33K$5.89M
Soros fund management120.37K0.07%120.37K$4.84M

Sold Out

HolderChange
Financial gravity asset management-2.00
Capital performance advisors llp-3.00
Riggs asset managment-7.00
Nelson, van denburg & campbell wealth management group-8.00
Cva family office-12.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024180-0.55%71,156,6423.18%931.14%88-4.35%59-4.84%
Sep 30, 202418116.03%68,964,5512.37%901.00%936.90%6231.91%
Jun 30, 2024155-4.32%67,367,8330.44%950.72%86-14.85%4711.90%
Mar 31, 202416220.00%67,073,03411.04%1141.07%10148.53%42-17.65%
Dec 31, 202313510.66%60,406,7775.38%1031.07%6811.48%5145.71%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
US Small-Cap Growth II Equity Comp3.09M4.78%-46.89K
T. Rowe Price New Horizons3.09M4.76%-
Vanguard Health Care Inv2.35M3.63%525.72K
Fidelity Growth Compy Commingled Pl O2.24M3.46%52.60K
Fidelity Growth Compy Commingled Pl S1.93M2.97%-250.03K
Vanguard US Total Market Shares ETF1.54M2.38%1.91K
Vanguard Total Stock Mkt Idx Inv1.54M2.37%1.66K
Fidelity Growth Company Fund1.35M2.07%-196.90K
Vanguard Small Cap Index1.24M1.91%1.01K
iShares Russell 2000 ETF1.24M1.91%-10.72K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 03, 2025Chiniara Ellen Chief Legal OfficerSell$55.59K
Mar 03, 2025Chiniara Ellen Chief Legal OfficerSell$12.65K
Mar 03, 2025Chadwick Jeremy G Chief Operating OfficerSell$34.30K
Mar 03, 2025Chadwick Jeremy G Chief Operating OfficerSell$7.81K
Mar 03, 2025Jacobs Bruce N. Chief Financial OfficerSell$174.50K

Insider Transactions Trends


DateBuySell
2025 Q2--
2025 Q1-9
2024 Q4-1
2024 Q3516
2024 Q2-9

KYMR Ownership FAQ


Who Owns Kymera Therapeutics?

Kymera Therapeutics shareholders are primarily institutional investors at 93.47%, followed by 1.31% insiders and 5.22% retail investors. The average institutional ownership in Kymera Therapeutics's industry, Biotech Stocks , is 68.48%, which Kymera Therapeutics exceeds.

Who owns the most shares of Kymera Therapeutics?

Kymera Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (6.87M shares, 9.03%), Baker bros. advisors lp (6M shares, 7.88%), and Wellington management group llp (5.31M shares, 6.97%). Together, they hold 23.87% of Kymera Therapeutics’s total shares outstanding.

Does Blackrock own Kymera Therapeutics?

Yes, BlackRock owns 5.87% of Kymera Therapeutics, totaling 4.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 124.04M$. In the last quarter, BlackRock increased its holdings by 499.77K shares, a 13.67% change.

Who is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested, with 24.03% of its assets in 4.9M Kymera Therapeutics shares, valued at 196.98M$.

Who is the top mutual fund holder of Kymera Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Kymera Therapeutics shares, with 4.78% of its total shares outstanding invested in 3.09M Kymera Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools